Jinwon Life Sciences Wins Grand Prize for 'Most Promising Vaccine Sector in Korea' at AVEA

GeneOne Life Science announced on the 29th that it won the Grand Prize for the "Most Promising Vaccine Sector in South Korea" at the Asia-Pacific Vaccine Excellence Award (AVEA) ceremony, held as part of the "5th Annual World Vaccine Asia Congress 2023" at the Marina Bay Sands Convention Center in Singapore.

The Asia-Pacific Vaccine Excellence Award (AVEA) was established to recognize outstanding achievements and excellence in various vaccine pharmaceutical-related latest technological developments, including vaccine research and development, raw material production, and vaccine supply chain improvements within the Asia-Pacific vaccine community.

This year, the award was given to the top leaders in the Asia-Pacific vaccine industry who demonstrated the latest technologies and best practices in epidemic vaccine R&D and manufacturing, in response to the need for new vaccine development following the COVID-19 pandemic.

The company stated, "Research Director Kim Won-il attended as the award recipient and, through panel discussions and presentations at the '5th Annual World Vaccine Asia Congress 2023,' explained our company's plasmid DNA vaccine R&D achievements and the latest R&D trends based on mRNA and circular RNA platforms, as well as introduced the excellence of our subsidiary VGXI's plasmid DNA production capabilities."

Park Young-geun, CEO of GeneOne Life Science, said, "We are pleased to have our vaccine development technological capabilities recognized based on the clinical trial results of plasmid DNA vaccines accumulated through nucleic acid-based vaccine research and development," adding, "We will also devote our efforts to new cancer vaccine and therapeutic research and development using the mRNA and circular RNA platforms completed through our own R&D technology."